Post-earnings recap
Reported
Tue, May 6, 2025
EPS actual
$1.20
EPS est.
$1.38
EPS surprise
-13.23%
1-day move
-14.06%
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report indicates that Krystal Biotech is facing challenges, particularly reflected in their lower-than-expected EPS. The stock's significant drop of 14.06% suggests that investors are reacting negatively to the missed expectations and lack of guidance. The company's focus on long-term growth may help in the future, but immediate concerns are weighing heavily on investor sentiment.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.20 | N/A | -13.23% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed concern over recent performance but remains committed to their strategic objectives. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term growth despite current setbacks.